ASPEN PHARMACARE HOLDINGS LIMITED - Changes to the Board

Changes to the Board

ASPEN PHARMACARE HOLDINGS LIMITED
(Incorporated in the Republic of South Africa)
Registration number 1985/0002935/06
Share code: APN
ISIN: ZAE000066692
(“Aspen” or “the Company”)


Resignation and Appointment of Directors

Shareholders are advised that Abbas Hussain has confirmed that he intends to tender his
resignation as a director of the Company with effect from 1 February 2015 due to a change in
his responsibilities at GlaxoSmithKline (“GSK”). David Redfern has been nominated by GSK to
replace Abbas as its nominee director on the Aspen Board with effect from that date. David is
GSK’s Chief Strategy Officer and the Chairman of ViiV Healthcare Limited. His extensive
expertise in the international pharmaceutical industry is expected to add value to Aspen.

The Board wishes to express its sincere appreciation to Abbas for his valuable contribution to
Aspen over the past 5 years and wish him every success in his future endeavours.


Durban
9 December 2014


Sponsor
Investec Bank Limited

Date: 10/12/2014 08:30:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). 
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
 the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, 
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
 information disseminated through SENS.